Dyadic International, Inc. Files 8-K: Material Agreement

TL;DR

Dyadic Intl (DYAI) signed a material definitive agreement on 6/27. Details to follow.

AI Summary

On June 27, 2024, Dyadic International, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. Dyadic International, Inc. is incorporated in Delaware and its principal executive offices are located in Jupiter, FL.

Why It Matters

This 8-K filing indicates a significant new agreement for Dyadic International, Inc., which could impact its business operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Players & Entities

• Dyadic International, Inc. (company) — Registrant
• June 27, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Jupiter, FL (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock , par value $0.001 per share DYAI The NASDAQ Stock Mark
• $500,000 — l receive an initial upfront payment of $500,000. Dyadic will receive a second payment o

Filing Documents

• dyai20240627_8k.htm (8-K) — 30KB
• ex_693312.htm (EX-10.1) — 93KB
• ex_693313.htm (EX-99.1) — 10KB
• ex_693313img001.jpg (GRAPHIC) — 3KB
• 0001437749-24-021876.txt ( ) — 288KB
• dyai-20240701.xsd (EX-101.SCH) — 3KB
• dyai-20240701_def.xml (EX-101.DEF) — 11KB
• dyai-20240701_lab.xml (EX-101.LAB) — 15KB
• dyai-20240701_pre.xml (EX-101.PRE) — 11KB
• dyai20240627_8k_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On June 27, 2024, Dyadic International, Inc. ("Dyadic") entered into a License and Development Agreement (the "Agreement") with Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals ("Proliant"), pursuant to which Proliant will license Dyadic's proprietary fungal microbial expression and production platforms and microbial strains from Dyadic for the production of recombinant serum albumin. Under the terms of the Agreement, Dyadic will receive an initial upfront payment of $500,000. Dyadic will receive a second payment of $500,000 upon the completion of the transfer of a Production Strain (as defined in the Agreement.) Dyadic will receive a final payment of $500,000 upon the meeting of a certain productivity threshold. Dyadic also will receive a share of the profits received by Proliant from the sale of animal-free recombinant serum albumin products produced pursuant to the Agreement. The foregoing description of the Agreement is only a summary of the material terms thereof, does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 28 , 2 024, Dyadic issued a press release related to the Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference, other than the third and fourth paragraphs of the press release.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 10.1 (1) License and Development Agreement between Dyadic International, Inc. and Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals, dated June 27, 2024. 99.1 Dyadic International, Inc. Press Release Dated June 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) (1) Certain provisions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 02, 2024 Dyadic International, Inc. By: /s/ Mark A. Emalfarb Name: Mark A. Emalfarb Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR